Skip to main content
COMPLETED RESEARCH: PRACTICE MANAGEMENT
Abstract #PM02

Impact of Drug Repository Program in a Rural Oncology Clinic

JHOP - March 2021 Vol 11 Special Feature - HOPA Abstracts, Adverse Events

Presenter: Stephanie Evangelisti, PharmD, MS, BCOP, Oncology Pharmacy Director, Grand Valley Oncology (Community Hospital), CO

Co-Authors: Brenda Butchko, CPhT, Grand Valley Oncology, CO; Alisha Reynolds, Grand Valley Oncology, CO

Background: Rules adopted in 2008, but repealed in 2020, by the Colorado State Legislature and State Board of Pharmacy, allowed patients with cancer or the patient’s family member to donate previously dispensed oral cancer medications to pharmacies for the purpose of redispensing to patients who cannot afford their prescribed medications.1 Because 16% of the population in Mesa County, Colorado, live below the poverty line, Grand Valley Oncology opted to participate in this drug recycling program to increase access and minimize waste of expensive oral cancer medications.

Objective: To determine the impact of the Cancer Drug Repository Program in terms of increased patient access to oral medications used in the treatment of cancer, including side-effect management, and decreased pharmaceutical waste.

Methods: Donations of noncontrolled medications received between January 1, 2019, and December 31, 2019, were reviewed by a pharmacist to ensure that the following conditions were met: used in the treatment of cancer, including side-effect management; stored in the original, unopened, sealed, and tamper-evident packaging; properly stored at room temperature; and within expiration date. If a patient undergoing cancer treatment was uninsured, underinsured, or demonstrated significant financial need, then a financial counselor would meet with the patient to review applicable medication access programs, such as the Cancer Drug Repository Program, manufacturer assistance programs, and grants. The patient, if eligible to participate, was required to acknowledge receipt of donated medication.

Results: A total of 34 medications were donated to the Cancer Drug Repository Program between January 1, 2019, and December 31, 2019. The total average sales price (ASP) for these donated medications was $569,592. Six patients were deemed eligible to participate in the program based on financial need and availability of donated medication; 12 prescriptions (ASP, $240,854) of the available 34 were dispensed to these individuals at the time of repeal.

Conclusion: Financial toxicity can be a significant burden to individuals diagnosed with cancer and their families. Although assistance was limited based on the availability of donated medications, the practice still promoted improved access to oral cancer medications. Resources, such as the drug recycling program, should be utilized to help increase patient access to, and minimize waste of, expensive oral cancer medications. This project was undertaken as a Quality Improvement Initiative at Colorado West Healthcare System (Grand Valley Oncology) and, as such, was not formally supervised by an Institutional Review Board.

  1. Colorado Department of Regulatory Agencies; State Board of Pharmacy. Rule 3.00.80 Return or Exchange of Drugs, Prescriptions, Medical Devices, and Medical Supplies for Dispensing or Donation. HB15-1039, General Assembly of the State of Colorado, 2015.
Related Items
Arthralgia Rates and Treatment Among Patients Receiving Bevacizumab-awwb Versus Bevacizumab
JHOP - August 2026 Vol 16, No 4 published on April 3, 2026 in Original Research, Adverse Events, Biosimilars
Characterizing Lenalidomide Dose Modifications Among Black and Non-Black Patients Receiving Induction Therapy for Newly Diagnosed Multiple Myeloma
JHOP - October 2026 Vol 16, No 5 published on March 23, 2026 in Original Research, Adverse Events, Disparities in Oncology Care, Dose Escalation/Reduction, Immunotherapy, Multiple Myeloma
Outcomes of Early Versus Delayed Initiation of Immunotherapy in Patients With Extensive-Stage Small Cell Lung Cancer
JHOP - August 2026 Vol 16, No 4 published on March 11, 2026 in Original Research, Lung Cancer, Immunotherapy, Adverse Events
Evaluation of a Biosimilar Conversion in an Academic Medical Center Outpatient Infusion Center
JHOP - March 2026 Vol 16 Special Feature published on March 3, 2026 in HOPA Abstracts
Outcomes of Supportive Care Versus Pharmacologic Intervention for the Management of CRS in Relapsed or Refractory Multiple Myeloma Treated With BCMA- and GPRC5D-Directed Bispecifics
JHOP - March 2026 Vol 16 Special Feature published on March 3, 2026 in HOPA Abstracts
From Diagnosis to Decision-Making: Black Patient and Caregiver Perspectives on Lung Cancer Care and Support Needs
JHOP - March 2026 Vol 16 Special Feature published on March 3, 2026 in HOPA Abstracts
Safety of Live-Attenuated MMR Vaccination in Patients With Multiple Myeloma Receiving Daratumumab After Autologous Stem-Cell Transplantation
JHOP - March 2026 Vol 16 Special Feature published on March 3, 2026 in HOPA Abstracts
A Real-World Analysis of Filgrastim and Biosimilars for Engraftment After Hemopoietic Cell Transplantation: Balancing Efficacy and Economics
JHOP - March 2026 Vol 16 Special Feature published on March 3, 2026 in HOPA Abstracts
Impact of an Oncolytic Pharmacist Prescription Verification Queue at an Academic Medical Center
JHOP - March 2026 Vol 16 Special Feature published on March 3, 2026 in HOPA Abstracts
Dexamethasone Versus Tocilizumab for Management of Talquetamab-Induced Cytokine Release Syndrome in Patients With Relapsed/Refractory Multiple Myeloma: A Multicenter, Retrospective Study
JHOP - March 2026 Vol 16 Special Feature published on March 3, 2026 in HOPA Abstracts